Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Lung Neoplasms 28Carcinoma, Non-Small-Cell Lung 21Urinary Bladder Neoplasms 3Melanoma 3Colorectal Neoplasms 3Adenocarcinoma of Lung 3Urogenital Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Colitis 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Radiation Pneumonitis 1Prostatic Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma 1Hematologic Neoplasms 1Glioma 1

Interventions

irinotecan sucrosofate 1atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Disulfides × Thoracic × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡